XML 47 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Stock-Based Compensation  
Summary of stock option activity

The following table summarizes the stock option transactions during the three months ended March 31, 2025 (in thousands, except per share data):

Weighted-

    

    

    

average

    

 

Weighted-

Remaining

 

Number of

average

Contractual

Aggregate

 

Options

Exercise

Life

Intrinsic

 

Stock Options

    

Outstanding

    

Price

    

(in years)

    

Value

 

Balance as of January 1, 2025

1,175

$

5.16

 

3.16

$

Granted

 

 

Exercised

 

Canceled and expired

 

Balance as of March 31, 2025

 

1,175

$

5.16

 

2.92

$

Options exercisable as of March 31, 2025

 

1,175

$

5.16

 

2.92

$

Summary of restricted stock awards activity

A summary of activity related to restricted stock awards for the three months ended March 31, 2025 is presented below (in thousands, except per share data):

    

    

Weighted-Average

 

Grant Date

 

Stock Awards

    

Shares

    

Share Value

 

Non-vested as of January 1, 2025

1,541

$

2.84

Granted

 

114

$

2.18

Vested

 

(7)

$

13.42

Forfeited

(19)

$

2.87

Non-vested as of March 31, 2025

 

1,629

$

2.75

Summary of unvested at-risk performance shares

A summary of the status of our unvested at-risk, performance shares as of March 31, 2025 is presented below (in thousands, except per share data):

    

    

Weighted-Average

Grant Date

Stock Awards

    

Shares

    

Share Value

Non-vested as of January 1, 2025

301

$

2.28

Granted

 

151

(1)

$

2.23

Vested

 

(75)

$

2.28

Forfeited

$

Non-vested as of March 31, 2025

 

377

$

2.26

(1)The number of shares presented assumes the achievement of 100% of a target financial performance metric to be determined by the Company’s Compensation Committee and will be subject to an at-risk, performance shares agreement.
Summary of compensation costs related to stock-based awards

The following table summarizes compensation costs related to our stock-based awards (in thousands, except per share data):

Three Months Ended

March 31, 

    

2025

    

2024

 

Cost of revenue

$

63

$

105

Selling, general and administrative

 

472

 

553

Research and development

 

111

 

151

Net effect on net loss

$

646

$

809